Short‐term all‐cause mortality (within the first 30 days after the intervention) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes short‐term all‐cause mortality (within the first 30 days after the… compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention may leads to higher cardiovascular mortality a. Intervention vs placebo [30 weeks to… (low certainty).
1 finding from 1 review
Intervention not reported
Mortality during critical care unit admission Measured using mortality rate in intervention and comparison groups During critical care admission · mechanically ventilated adults with need for aerosol bronchodilator therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cost‐effectiveness of interventions (the study reviewed suicide data from a bridge and surrounding areas over a 70‐year period, and estimated reductions in mortality due to the barrier over a 20‐year period) · adults or children of all ethnicities
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs meglitinide [d. 12 months to 17 m... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in cardiovascular mortality a. Intervention vs metformin [a. 24 weeks… (low certainty).
1 finding from 1 review
All‐cause mortality · adults with oesophageal varices
Band ligation probably leads to lower mortality compared with no intervention (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether charcoal haemoperfusion changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people with hepatorenal syndrome
Terlipressin may leads to lower mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
All‐cause mortality · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Non‐absorbable disaccharides probably leads to lower mortality compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Cardiac mortality · patients with restenosis after percutaneous coronary intervention in coronary heart disease
1 finding from 1 review
Cardiac mortality · patients with restenosis after percutaneous coronary intervention in coronary heart disease
1 finding from 1 review
All‐cause mortality · children (0 to 24 months)
Palivizumab showed no clear difference in mortality compared with placebo, no intervention or standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
All‐cause mortality
It is very uncertain whether L‐ornithine L aspartate changes mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality · patients undergoing a surgical intervention that induces kidney injury
The intervention showed no clear difference in mortality (high certainty).
1 finding from 1 review
RR 0.86 [0.54, 1.37]
Studies not reported
High